Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial
| Autor: | Hangzhong Li, Hong Luo, Dingwei Ye, Aiping Zhou, Xiubao Ren, Xianzhong Bai, Shukui Qin, Ji-Yan Liu, Yan Song, Xiaodong Xie, Yuxian Bai, Jinwan Wang, Cheng Fu, Jianhui Ma |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Cancer Research biology business.industry VEGF receptors Pharmacology Fibroblast growth factor medicine.disease respiratory tract diseases 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology Renal cell carcinoma 030220 oncology & carcinogenesis medicine biology.protein Cancer research Tumor growth Vegfr tki business |
| Zdroj: | Journal of Clinical Oncology. 34:e16082-e16082 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.e16082 |
| Popis: | e16082Background: Fibroblast growth factor (FGF) signaling regulates tumor growth and vascularization and partly mediates antiangiogenic escape from VEGFR inhibitors. Sequential TKI treatment has b... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|